myADA
Anti-drug antibody risk prediction — Next-generation in-silico ADA risk prediction
myADA delivers accurate, scalable, biologically grounded Anti-Drug Antibody (ADA)-risk prediction. It is a next-generation, in-silico tool centered on advanced MHC class II epitope immunogenicity modeling, powered by our proprietary algorithms. By accurately identifying CD4⁺ T-cell epitopes capable of initiating T-cell–dependent ADA responses, myADA supports proactive, design-stage control of biologic immunogenicity to accelerate antibody design and development.
What myADA delivers
We offer ADA risk prediction with a turnaround time of 1 week:
- High-risk candidate prediction: flagging and deprioritization of drug candidates with high likelihood of eliciting anti-drug antibodies
- Immunogenicity hotspot identification: identification of high-impact immunogenic epitope clusters across the antibody sequence
- Immunogenic hotspot re-engineering: re-engineering based on protein regions likely to be immunogenic in large populations, identification of MHC I/II immunogenic epitopes, and isolated immunogenicity hotspots
- Population-level impact assessment: interpolation of immunogenicity impact across the whole population
- Humanness profiling: quantification of human-like antibody sequences
- Similarity comparison to known antibodies: screening against a database of known antibodies for structural and functional similarity
Transform biologics data into actionable insights
To allow easy interpretation of complex biologics data, the data is presented in a user-friendly, web-based myADA platform specifically designed to provide a comprehensive and intuitive overview of biologics characteristics. With powerful analytics and intuitive visualization, it empowers researchers to identify and compare therapeutic targets and make data-driven decisions.
Frequently asked questions about myADA
What is myADA?
myADA is myNEO Therapeutics’ in-silico anti-drug antibody (ADA) risk prediction tool. It models MHC class II epitope immunogenicity to help biologics developers reduce immunogenicity risk at the design stage.
How does myADA help antibody development?
myADA flags high-risk candidates, identifies immunogenicity hotspots, supports hotspot re-engineering, assesses population-level impact, and profiles humanness and similarity to known antibodies.
What is the turnaround time for myADA?
ADA risk prediction with myADA has a turnaround time of 1 week.
Is there a myADA technology paper?
Yes. myNEO publishes a technology paper on myADA anti-drug antibody risk prediction, available from the myADA product page and publications library.
Ready to use myADA?
Talk to our team about integrating myADA into your discovery or development workflow.